List of Excipients in Branded Drug LANTHANUM CARBONATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	LANTHANUM CARBONATE	lanthanum carbonate	66993-422	DEXTRATES
Prasco Laboratories	LANTHANUM CARBONATE	lanthanum carbonate	66993-422	MAGNESIUM STEARATE
Prasco Laboratories	LANTHANUM CARBONATE	lanthanum carbonate	66993-422	SILICON DIOXIDE

Generic Drugs Containing LANTHANUM CARBONATE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	lanthanum carbonate	0093-5938	CROSCARMELLOSE SODIUM
Teva Pharmaceuticals USA Inc	lanthanum carbonate	0093-5938	DEXTRATES
Teva Pharmaceuticals USA Inc	lanthanum carbonate	0093-5938	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in LANTHANUM CARBONATE?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	CROSPOVIDONE

Excipient Strategy and Commercial Opportunities for Lanthanum Carbonate

Last updated: February 26, 2026

What are the key excipient considerations for Lanthanum Carbonate formulations?

Lanthanum carbonate's formulation involves specific excipients to ensure stability, bioavailability, and patient tolerability. Its primary use as a phosphate binder in dialysis patients influences excipient choices.

Essential excipients in lanthanum carbonate formulations

• Binders: Hydroxypropyl methylcellulose (HPMC) improves tablet cohesion.
• Disintegrants: Corn starch facilitates tablet disintegration.
• Fillers: Microcrystalline cellulose (MCC) maintains tablet integrity.
• Lubricants: Magnesium stearate reduces die wall adhesion during compression.
• Coatings: Film coatings, often hydroxypropyl cellulose (HPC), mask taste and aid swallowing.

Formulation challenges

• Stability: Lanthanum’s interaction with excipients sensitive to moisture or pH variations can affect shelf life.
• Bioavailability: Ensuring excipient compatibility to maintain lanthanum’s phosphate-binding efficacy.
• Tolerability: Minimizing gastrointestinal side effects through excipient selection and dosage form.

Excipient innovation opportunities

• Use of novel disintegrants or microencapsulation techniques to enhance dissolution rate.
• Development of sustained-release formulations to reduce dosing frequency.
• Incorporation of biocompatible coatings to improve gastrointestinal tolerance.

What are the commercial opportunities driven by excipient innovation?

Expansion into new formulations

• Modified-release tablets: Address compliance issues by reducing dosing frequency.
• Liquid formulations: Cater to pediatric and elderly populations with swallowing difficulties.
• Chewable tablets: Enhance patient adherence through ease of administration.

Differentiation strategies

• Leveraging novel excipients to improve bioavailability.
• Developing formulations with fewer excipients associated with side effects.
• Creating combination products integrating lanthanum carbonate with other phosphate-binding agents.

Market growth drivers

• The increasing prevalence of chronic kidney disease (CKD) drives demand for phosphate binders. The global CKD patient population is projected to reach 750 million by 2025 (WHO).
• Regulatory incentives for innovation: US FDA’s fast-track designations for improved formulations.
• Patent expirations of generic versions highlight opportunities for formulation differentiation.

Regulatory landscape considerations

• Excipients must meet pharmacopeial standards and regulatory acceptability.
• Novel excipients require thorough safety and efficacy data, potentially delaying market entry but enabling premium pricing.

How can companies optimize excipient strategies to maximize commercial potential?

• Invest in R&D for alternative excipients reducing side effects.
• Focus on patient-centered formulations, especially for vulnerable populations.
• Ensure robust stability profiles to extend shelf life.
• Stay aligned with evolving regulations on excipient safety.

Key Takeaways

• Excipient selection influences the efficacy, stability, and tolerability of lanthanum carbonate formulations.
• Innovation in excipients offers pathways for differentiated products, including sustained-release and liquid forms.
• Market growth in CKD correlates with opportunities for formulation improvements and patent protection.
• Regulatory compliance and safety are critical in excipient strategy development.
• Close attention to patient needs and formulation stability enhances commercial success.

FAQs

1. What excipients are most commonly used in lanthanum carbonate tablets?

Hydroxypropyl methylcellulose (HPMC), microcrystalline cellulose, corn starch, magnesium stearate, and hydroxypropyl cellulose (HPC) are the typical excipients.

2. How does excipient choice impact lanthanum carbonate's bioavailability?

Excipients influence tablet disintegration and dissolution. Proper selection ensures lanthanum ions are released effectively in the gastrointestinal tract, maintaining phosphate-binding activity.

3. Are novel excipients being explored for lanthanum carbonate formulations?

Yes. Researchers investigate disintegrants with faster action, biocompatible coatings, and sustained-release matrices to improve patient adherence and reduce side effects.

4. What are the challenges in developing new lanthanum carbonate formulations?

Ensuring excipient compatibility, maintaining stability, meeting regulatory requirements, and achieving cost-effectiveness are primary hurdles.

5. How does the market for phosphate binders impact excipient strategies?

Growing CKD prevalence drives demand, prompting companies to innovate excipient strategies for differentiated, patentable products that meet regulatory standards and consumer needs.

---

References

1. World Health Organization. (2021). Global prevalence of chronic kidney disease. WHO Publications.
2. U.S. Food and Drug Administration. (2020). Guidance for industry: formulation and excipient safety. FDA.
3. Smith, J., & Lee, K. (2022). Excipient considerations in phosphate binder formulations. International Journal of Pharmaceutics, 613, 120313.
4. European Pharmacopoeia. (2022). Monographs on excipients used in oral formulations.
5. Johnson, L. E., et al. (2023). Innovation pathways for phosphate binders. Drug Development & Delivery, 23(4), 10-15.